Zheng Zhao (zz7r_at_virginia.edu)
Zheng Zhao (zz7r_at_virginia.edu)
Department of Biomedical Engineering and School of Data Science, University of Virginia
Verified email at mail.ustc.edu.cn
Title
Cited by
Cited by
Year
Developing irreversible inhibitors of the protein kinase cysteinome
Q Liu, Y Sabnis, Z Zhao, T Zhang, SJ Buhrlage, LH Jones, NS Gray
Chemistry & biology 20 (2), 146-159, 2013
4862013
Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Z Zhao, H Wu, L Wang, Y Liu, S Knapp, Q Liu, NS Gray
ACS chemical biology 9 (6), 1230-1241, 2014
2612014
Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor
HG Kim, L Tan, EL Weisberg, F Liu, P Canning, HG Choi, SA Ezell, H Wu, ...
ACS chemical biology 8 (10), 2145-2150, 2013
1082013
Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics
Q Liu, S Kirubakaran, W Hur, M Niepel, K Westover, CC Thoreen, J Wang, ...
Journal of Biological Chemistry 287 (13), 9742-9752, 2012
1002012
Brain penetrant LRRK2 inhibitor
HG Choi, J Zhang, X Deng, JM Hatcher, MP Patricelli, Z Zhao, DR Alessi, ...
ACS medicinal chemistry letters 3 (8), 658-662, 2012
982012
Progress with covalent small-molecule kinase inhibitors
Z Zhao, PE Bourne
Drug Discovery Today, 2018
802018
Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and …
E Weisberg, Q Liu, E Nelson, AL Kung, AL Christie, R Bronson, M Sattler, ...
Leukemia 26 (10), 2233-2244, 2012
632012
Determining cysteines available for covalent inhibition across the human kinome
Z Zhao, Q Liu, S Bliven, L Xie, PE Bourne
Journal of Medicinal Chemistry 60 (7), 2879–2889, 2017
572017
Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma
H Wu, W Wang, F Liu, EL Weisberg, B Tian, Y Chen, B Li, A Wang, ...
ACS chemical biology 9 (5), 1086-1091, 2014
492014
Discovery of a selective irreversible BMX inhibitor for prostate cancer
F Liu, X Zhang, E Weisberg, S Chen, W Hur, H Wu, Z Zhao, W Wang, ...
ACS Chemical Biology 8 (7), 1423-1428, 2013
382013
Drug repurposing to target Ebola virus replication and virulence using structural systems pharmacology
Z Zhao, C Martin, R Fan, PE Bourne, L Xie
BMC bioinformatics 17 (1), 90, 2016
352016
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia
H Wu, C Hu, A Wang, EL Weisberg, Y Chen, CH Yun, W Wang, Y Liu, ...
Leukemia 30 (1), 173-181, 2016
342016
Crystal structure of the GRAS domain of SCARECROW-LIKE7 in Oryza sativa
S Li, Y Zhao, Z Zhao, X Wu, L Sun, Q Liu, Y Wu
The Plant Cell 28 (5), 1025-1034, 2016
322016
Delineation of polypharmacology across the human structural kinome using a functional site interaction fingerprint approach
Z Zhao, L Xie, L Xie, PE Bourne
Journal of medicinal chemistry 59 (9), 4326-4341, 2016
282016
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
H Wu, A Wang, W Zhang, B Wang, C Chen, W Wang, C Hu, Z Ye, Z Zhao, ...
Oncotarget 6 (31), 31313, 2015
272015
Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
A Wang, XE Yan, H Wu, W Wang, C Hu, C Chen, Z Zhao, P Zhao, X Li, ...
Oncotarget 7 (43), 69760, 2016
262016
Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML
H Wu, C Hu, A Wang, EL Weisberg, W Wang, C Chen, Z Zhao, K Yu, J Liu, ...
Leukemia 30 (3), 754-757, 2016
232016
Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome
Z Zhao, L Xie, PE Bourne
PLoS One 12 (6), e0179936, 2017
212017
Discovery of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo [3, 4-d] pyrimidin-1-yl) piperidin-1-yl)-2-(dimethylamino) ethanone (CHMFL-FLT3-122) as a Potent and Orally …
X Li, A Wang, K Yu, Z Qi, C Chen, W Wang, C Hu, H Wu, J Wu, Z Zhao, ...
Journal of Medicinal Chemistry 58 (24), 9625–9638, 2015
182015
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
A Wang, H Wu, C Chen, C Hu, Z Qi, W Wang, K Yu, X Liu, F Zou, Z Zhao, ...
Oncotarget 7 (20), 29131, 2016
142016
The system can't perform the operation now. Try again later.
Articles 1–20